查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971312

朊病毒疾病治疗市场－全球产业规模、份额、趋势、机会与预测：按类型、药物、地区和竞争格局划分，2021-2031年

Prion Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity & Forecast Segmented By Type (Human Prion Diseases, Animal Prion Diseases), By Drug (Antidepressant, Antipsychotic Agents), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球朊病毒疾病治疗市场预计将从 2025 年的 51.9 亿美元成长到 2031 年的 68.8 亿美元，复合年增长率为 4.81%。

此领域涵盖旨在控製或改变由异常蛋白质折迭引起的致命性神经退化性疾病（例如库贾氏病）病程的药物疗法的开发和商业化。市场成长主要由诊断技术的进步所驱动，这些进步使得早期检测和以反义寡核苷酸和单株抗体为中心的重点监测倡议成为可能。根据美国国家朊病毒疾病病理监测中心的数据，2024年在352例转诊病例中确诊了271例特定朊病毒疾病，凸显了对有效治疗方案的持续临床需求。

市场概览
预测期 2027-2031
市场规模：2025年 51.9亿美元
市场规模：2031年 68.8亿美元
复合年增长率：2026-2031年 4.81%
成长最快的细分市场 人类朊病毒病
最大的市场 北美洲

儘管存在这些积极因素，但由于这些疾病极为罕见，市场仍面临许多重大障碍。这种罕见性严重限制了符合临床试验条件的患者数量，阻碍了监管部门核准所需的数据收集和受试者招募，并经常导致潜在治疗方法从临床前阶段到商业化的进程延误。因此，製药公司在这一特殊治疗领域进行药物研发投资时，面临着巨大的财务和物流风险。

市场驱动因素

公共和私人研发资金的增加正在调动关键资源，以降低全球朊病毒疾病治疗研发的风险。政府机构和非营利组织正在加大投入，加速临床前研究，以满足这些致命疾病对有效治疗标靶的迫切需求。例如，根据美国卫生与公众服务部的报告，美国国立卫生研究院 (NIH) 将于 2025 年向博德研究所津贴476,359 美元，用于支持先进的基因组学研究。除了公共投资外，私营非营利部门也在加大力度，弥合从发现到药物开发的差距。克雅氏病基金会在 2025 年 1 月的津贴申请开放公告中宣布，将向专门针对人类朊病毒疾病的研究计划提供最高 10 万美元的研究津贴。

同时，新型免疫疗法和基因疗法的涌现展现了缓解疾病介入的巨大潜力。研究机构正超越症状治疗，利用反义寡核苷酸和碱基编辑等技术靶向异常蛋白的产生，早期研究证实了令人鼓舞的结果。 2025年4月，《哈佛公报》发表了报导，报导了一种新的基因编辑策略降低了毒性蛋白水平，并将接受治疗的小鼠的寿命延长了52%。这些进展凸显了朊病毒疾病治疗方法开发平臺的成熟度，以及在实现首个朊病毒疾病根治性治疗方法方面所取得的竞争优势。

市场挑战

合格临床实验参加者的短缺是市场扩张的主要障碍，并从根本上阻碍了潜在治疗方法的临床开发进程。与较常见的神经退化性疾病不同，朊病毒病患者群体地域分散且规模极小，难以招募符合监管部门核准所需的具有统计意义的队列。这种分散性迫使製药开发商设立众多国际临床实验中心以确保达到最低参与者数量，这显着增加了营运成本和后勤复杂性。此外，由于这些疾病进展迅速，许多患者在确诊时已不再符合试验条件，导致筛检失败率高，并进一步延误了研究的完成。

患者群体的这种固有限制直接限制了商业性兴趣和投资。据克雅氏病基金会（CJD Foundation）称，即使到2024年，美国每年新增病例数仍将维持在500例左右。如此有限的目标市场使得生物製药公司面临不利的风险回报比，因为很难证明药物研发的高昂固定成本与有限患者群体带来的预期收益之间的合理性。因此，这种情况常常导致一些有前景的候选药物在早期研发阶段停滞不前，无法进入上市所需的临床实验阶段。

市场趋势

人工智慧 (AI) 在朊病毒疾病药物研发中的应用，透过解析异常蛋白复杂的结构动态，从根本上改变了治疗标靶的识别方式。先进的机器学习演算法能够预测 PrPSc（异常朊病毒蛋白）的瞬态结构，这在以前由于缺乏高分辨率结构数据而十分困难，并且还能识别小分子的隐藏结合位点。这种计算方法显着缩短了先导化合物的最佳化週期，并透过在物理合成之前筛选候选化合物，提高了临床成功的机率。在 2026 年 1 月发布的一份关于与 Unravel Biosciences 合作的新闻稿中，EvoGene 预测，将其生成式 AI 平台整合到开发平臺中，将加速药物发现进程，并直接促成计划于 2026 年推出的四项针对神经退化性疾病的新临床试验。

同时，将RT-QuIC生物标记整合到临床试验设计中，可以有效解决患者分层和招募的瓶颈问题。透过将即时震盪诱导转化试验（RT-QuIC）作为主要入组标准，研发人员可以确保在先兆期识别出合格的受试者，从而减少筛检失败，并保证研究队列具有活跃的朊病毒种子活性。这种精准性对于证明治疗效果至关重要，尤其对于那些病情恶化迅速、标准临床终点无法捕捉疗效的患者族群。根据梅奥诊所研究所2025年2月发表的一篇报导，脑脊髓液检测的广泛临床应用将使医护人员能够在患者丧失功能独立性之前（通常在两年内）确认诊断并确定其合格试验资格。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球朊病毒疾病治疗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按类型（人类朊病毒病、动物朊病毒病）
    • 依药物类型（抗忧郁剂、抗精神病药）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美朊病毒病治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲朊病毒疾病治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区朊病毒疾病疗法的市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲朊病毒病治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲朊病毒病治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球朊病毒疾病治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Fresenius SE & Co. KGaA
  • Elite Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • Novartis AG
  • Merck KGaA
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Cipla Ltd
  • Teva Pharmaceuticals Industries Ltd
  • Abbott Laboratories

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 17004

The Global Prion Disease Treatment Market is projected to expand from USD 5.19 Billion in 2025 to USD 6.88 Billion by 2031, registering a compound annual growth rate of 4.81%. This sector encompasses the development and commercialization of pharmaceutical therapies designed to manage or alter the course of fatal neurodegenerative disorders arising from misfolded proteins, such as Creutzfeldt-Jakob Disease. Market growth is largely fueled by improvements in diagnostic technologies that allow for earlier detection, alongside focused research initiatives centering on antisense oligonucleotides and monoclonal antibodies. According to the National Prion Disease Pathology Surveillance Center, 271 specific prion disease cases were confirmed from 352 referrals in 2024, emphasizing the persistent clinical necessity for effective therapeutic options.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.19 Billion
Market Size 2031USD 6.88 Billion
CAGR 2026-20314.81%
Fastest Growing SegmentHuman Prion Diseases
Largest MarketNorth America

Despite these positive drivers, the market confronts substantial obstacles due to the extreme rarity of these diseases, which severely restricts the pool of patients eligible for clinical trials. This scarcity hampers recruitment efforts and the data collection necessary for regulatory approval, frequently stalling the movement of potential therapies from preclinical stages to commercial release. Consequently, pharmaceutical firms encounter significant financial and logistical hazards when investing in drug development for this specialized therapeutic area.

Market Driver

The increase in public and private R&D funding is mobilizing critical resources to reduce the risks associated with therapeutic development in the Global Prion Disease Treatment Market. Government agencies and non-profit organizations are boosting financial commitments to accelerate preclinical research, addressing the urgent requirement for viable targets in these fatal conditions. For example, the U.S. Department of Health and Human Services reported that in 2025, the National Institutes of Health granted $476,359 to the Broad Institute to support advanced genomic research. Complementing this public investment, the private non-profit sector is scaling up efforts to bridge the gap between discovery and drug development; the CJD Foundation announced in its January 2025 'Request for 2024-25 Grant Applications' that it would award research grants of up to $100,000 for projects specifically focused on human prion diseases.

Concurrently, the emergence of novel immunotherapy and gene therapy pipelines is introducing potential disease-modifying interventions. Research entities are moving beyond symptomatic relief, utilizing modalities such as antisense oligonucleotides and base editing to target the fundamental production of misfolded proteins, with early studies showing promising efficacy. In April 2025, the Harvard Gazette reported in 'Team hits milestone toward prion disease treatment' that a new gene-editing strategy successfully lowered toxic protein levels and extended the lifespans of treated mice by 52 percent. These advancements highlight the maturation of the pipeline and the competitive drive to deliver the first curative treatments for prion disorders.

Market Challenge

The scarcity of eligible trial participants presents a formidable barrier to market expansion, fundamentally disrupting the clinical development timeline for potential therapies. Unlike more common neurodegenerative disorders, the patient population for prion diseases is geographically dispersed and exceptionally small, complicating the recruitment of statistically significant cohorts required for regulatory approval. This fragmentation compels pharmaceutical developers to establish numerous international trial sites to secure a minimal number of participants, a requirement that exponentially increases operational costs and logistical complexity. Furthermore, the rapid progression of these conditions often renders patients ineligible for participation by the time a definitive diagnosis is confirmed, resulting in high screen-failure rates that further delay study completion.

This inherent volume constraint directly limits commercial interest and investment. According to the CJD Foundation, in 2024, the annual incidence in the United States remained limited to nearly 500 new cases per year. Such a restricted addressable market creates an unfavorable risk-to-reward ratio for biopharmaceutical entities, as the high fixed costs of drug development are difficult to justify against the projected revenue from such a finite patient base. Consequently, this dynamic frequently stalls promising candidates in early-stage research, preventing them from advancing to the pivotal trials necessary for market entry.

Market Trends

The application of Artificial Intelligence in prion drug discovery is fundamentally reshaping the identification of therapeutic targets by decoding the complex structural dynamics of misfolded proteins. Advanced machine learning algorithms are now being utilized to predict the transient conformations of PrPSc and identify cryptic binding pockets for small molecules, a task previously hindered by the lack of high-resolution structural data. This computational approach significantly compresses the timeline for lead optimization and improves the probability of clinical success by filtering candidates before physical synthesis. According to Evogene Ltd., in a January 2026 press release regarding their collaboration with Unravel Biosciences, the integration of generative AI platforms into the development pipeline is projected to accelerate the discovery process, directly contributing to the initiation of four new clinical trials for neurodegenerative conditions starting in 2026.

Simultaneously, the integration of RT-QuIC biomarkers in clinical trial design is addressing the critical bottleneck of patient stratification and recruitment. By incorporating Real-Time Quaking-Induced Conversion assays as a primary inclusion criterion, developers can now definitively identify eligible participants at the prodromal stage, thereby reducing screen failures and ensuring that study cohorts exhibit active prion seeding activity. This precision is vital for demonstrating therapeutic efficacy in a rapidly deteriorating patient base where standard clinical endpoints are often too slow to capture treatment effects. According to a February 2025 article by Mayo Clinic Laboratories, the widespread clinical deployment of this cerebrospinal fluid assay now enables providers to confirm a diagnosis and determine trial eligibility before patients lose functional independence, a period often spanning less than two years.

Key Market Players

  • Fresenius SE & Co. KGaA
  • Elite Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • Novartis AG
  • Merck KGaA
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Cipla Ltd
  • Teva Pharmaceuticals Industries Ltd
  • Abbott Laboratories

Report Scope

In this report, the Global Prion Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prion Disease Treatment Market, By Type

  • Human Prion Diseases
  • Animal Prion Diseases

Prion Disease Treatment Market, By Drug

  • Antidepressant
  • Antipsychotic Agents

Prion Disease Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prion Disease Treatment Market.

Available Customizations:

Global Prion Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prion Disease Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Human Prion Diseases, Animal Prion Diseases)
    • 5.2.2. By Drug (Antidepressant, Antipsychotic Agents)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Prion Disease Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Drug
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Prion Disease Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Drug
    • 6.3.2. Canada Prion Disease Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Drug
    • 6.3.3. Mexico Prion Disease Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Drug

7. Europe Prion Disease Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Drug
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Prion Disease Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Drug
    • 7.3.2. France Prion Disease Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Drug
    • 7.3.3. United Kingdom Prion Disease Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Drug
    • 7.3.4. Italy Prion Disease Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Drug
    • 7.3.5. Spain Prion Disease Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Drug

8. Asia Pacific Prion Disease Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Drug
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Prion Disease Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Drug
    • 8.3.2. India Prion Disease Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Drug
    • 8.3.3. Japan Prion Disease Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Drug
    • 8.3.4. South Korea Prion Disease Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Drug
    • 8.3.5. Australia Prion Disease Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Drug

9. Middle East & Africa Prion Disease Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Drug
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Prion Disease Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Drug
    • 9.3.2. UAE Prion Disease Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Drug
    • 9.3.3. South Africa Prion Disease Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Drug

10. South America Prion Disease Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Drug
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Prion Disease Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Drug
    • 10.3.2. Colombia Prion Disease Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Drug
    • 10.3.3. Argentina Prion Disease Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Drug

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Prion Disease Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Fresenius SE & Co. KGaA
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Elite Pharmaceuticals Inc
  • 15.3. Ionis Pharmaceuticals Inc
  • 15.4. Novartis AG
  • 15.5. Merck KGaA
  • 15.6. AstraZeneca PLC
  • 15.7. Bristol-Myers Squibb Company
  • 15.8. Cipla Ltd
  • 15.9. Teva Pharmaceuticals Industries Ltd
  • 15.10. Abbott Laboratories

16. Strategic Recommendations

17. About Us & Disclaimer